언어 선택

LILRA4

LILRA4 분자 정보

영어 이름	Leukocyte immunoglobulin-like receptor subfamily A member 4	시판 약물 수	0
임상 약물 수	1	표적 별명	ILT7，CD85g，Immunoglobulin-like transcript 7，LILRA4，Leukocyte Immunoglobulin Like Receptor A4，Leukocyte Immunoglobulin-Like Receptor， Subfamily A (With TM Domain)， Member 4，CD85 Antigen-Like Family Member G，Leucocyte Ig-Like Receptor A4，Leukocyte Immunoglobulin-Like Receptor， Subfamily A (Without TM Domain)， Member 4，Leukocyte Immunoglobulin-Like Receptor Subfamily A Member 4，CD85g Antigen，ILT-7
최고 연구 개발 단계	Phase 2 Clinical

영어 이름	Leukocyte immunoglobulin-like receptor subfamily A member 4
표적 별명	ILT7，CD85g，Immunoglobulin-like transcript 7，LILRA4，Leukocyte Immunoglobulin Like Receptor A4，Leukocyte Immunoglobulin-Like Receptor， Subfamily A (With TM Domain)， Member 4，CD85 Antigen-Like Family Member G，Leucocyte Ig-Like Receptor A4，Leukocyte Immunoglobulin-Like Receptor， Subfamily A (Without TM Domain)， Member 4，Leukocyte Immunoglobulin-Like Receptor Subfamily A Member 4，CD85g Antigen，ILT-7
시판 약물 수	0
임상 약물 수	1
최고 연구 개발 단계	Phase 2 Clinical

LILRA4 제품 목록

속성
Protein (2)
제품 라이브러리
온라인 (2)
종
Human (2)
태그
His Tag (2)
마커
Unconjugated (2)

제품 번호	종	발현 시스템	제품 설명	단백질 구조	순도	특성
LI4-H5243	Human	HEK293	Human LILRA4 / CD85g / ILT7 Protein, His Tag (MALS verified)
LI4-H52H5	Human	HEK293	Human LILRA4 / CD85g / ILT7 Protein, His Tag

총 수량2

LILRA4분자 배경

Leukocyte immunoglobulin-like receptor subfamily A member 4 (LILRA4/ILT7/CD85g) is a marker of plasmacytoid dendritic cells (pDCs), which are reported to be a major source of the abnormally high levels of IFNα associated with autoimmune diseases. Targeting LILRA4 with therapeutic antibodies to promote killing of these IFNα-producing pDCs is being investigated as a novel approach to alleviating the symptoms of autoimmune diseases. LILRA4 is an immunoglobulin-like protein preferentially expressed on the surface of human plasmacytoid dendritic cells (pDCs). It interacts with bone marrow stromal cell antigen 2 to control the Toll-like receptor (TLR) driven response by pDCs to viral infection. It may also be involved in modulating pDC-tumour interactions. pDCs are a source of the excess IFNα which drives autoimmune disease symptoms.

LILRA4분자 별명

LILRA4,CD85g,ILT7,ILT-7

임상 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	적응증	임상 시험
Daxdilimab	MEDI-7734; VIB-7734; HZN-7734	Phase 2 Clinical	Horizon Therapeutics PLC, Sbi Biotech Co Ltd	Acute Lung Injury; Alopecia Areata; Dermatomyositis; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Lupus Nephritis; Myositis; Polymyositis; Scleroderma, Systemic; Sjogren's Syndrome	상세